| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | Chief Scientific Officer | Common Stock | 67,845 | $1,029,208 | $15.17 | 05 Jan 2026 | Direct |
| Monte Rosa Therapeutics, Inc. | Chief Scientific Officer | Stock Option (Right to Buy) | 158,000 | 02 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | 02 Jan 2026 | 3 | -$47,861 | 4 | Chief Scientific Officer | 05 Jan 2026, 16:04 |
| GLUE | Monte Rosa Therapeutics, Inc. | 02 Jan 2025 | 2 | $0 | 4 | Chief Scientific Officer | 06 Jan 2025, 16:15 |
| GLUE | Monte Rosa Therapeutics, Inc. | 03 Jun 2024 | 1 | $0 | 4 | Chief Scientific Officer | 05 Jun 2024, 16:10 |
| GLUE | Monte Rosa Therapeutics, Inc. | 28 May 2024 | 0 | $0 | 3 | Chief Scientific Officer | 05 Jun 2024, 16:05 |
| GLUE | Monte Rosa Therapeutics, Inc. | 03 Jan 2023 | 1 | $0 | 4 | Chief Technology Officer | 04 Jan 2023, 15:31 |
| GLUE | Monte Rosa Therapeutics, Inc. | 01 Mar 2022 | 1 | $0 | 4 | Chief Technology Officer | 02 Mar 2022, 17:46 |
| GLUE | Monte Rosa Therapeutics, Inc. | 23 Jun 2021 | 0 | $0 | 3 | Chief Technology Officer | 23 Jun 2021, 20:32 |